Page 19 - Lipids News Today

The first-in-human HEART-1 trial of in vivo DNA editing called VERVE-101, shows reductions in LDL and PCSK9 protein in patients with familial hypercholesterolemia.

Plasma ceramides and sphingomyelins with palmitic acid were linked to a 34% and 37% increased risk of sudden cardiac death (SCD) per higher SD of log sphingolipid levels, respectively.

For 1 in 4 patients with primary biliary cholangitis (PBC) who received the investigational PPAR-delta agonist, alkaline phosphatase levels normalized.

Up to half of RA patients in the United States use long-term glucocorticoids despite previous work suggesting they increase MACE in a dose-dependent way.

In two studies run in parallel, testing different strategies, automatic referral to a pharmacist was superior to EHR alerts for increasing statin prescriptions for at-risk patients.

Though some may still consider it to be pseudoscience, the positive data behind social connection is hard to deny. And its easy for physicians to push.

In an early phase multicenter study, reductions in lipoprotein(a) to undetectable levels were achieved with a small interfering RNA therapeutic, lepodisiran.

A new PCSK9 inhibitor (recaticimab) injected every one to three months may work safely and provide more flexible dosing to lower cholesterol, according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2023.

A first-of-its-kind study aimed to determine if treating age-related hearing loss could prevent cognitive decline.

A comprehensive review of the nutritional and therapeutic benefits of edible flowers highlights their role in health, food security, and environmental sustainability. This study provides insight into the nutritional content of flowers, their potential health benefits due to bioactive compounds, and innovative sustainable uses like phytoremediation and natural dyes.